SG11202002113TA - Niraparib formulations - Google Patents
Niraparib formulationsInfo
- Publication number
- SG11202002113TA SG11202002113TA SG11202002113TA SG11202002113TA SG11202002113TA SG 11202002113T A SG11202002113T A SG 11202002113TA SG 11202002113T A SG11202002113T A SG 11202002113TA SG 11202002113T A SG11202002113T A SG 11202002113TA SG 11202002113T A SG11202002113T A SG 11202002113TA
- Authority
- SG
- Singapore
- Prior art keywords
- niraparib formulations
- niraparib
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762563535P | 2017-09-26 | 2017-09-26 | |
| PCT/US2018/052979 WO2019067634A1 (en) | 2017-09-26 | 2018-09-26 | NIRAPARIB FORMULATIONS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202002113TA true SG11202002113TA (en) | 2020-04-29 |
Family
ID=63858161
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202002113TA SG11202002113TA (en) | 2017-09-26 | 2018-09-26 | Niraparib formulations |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US11730725B2 (ja) |
| EP (1) | EP3687505A1 (ja) |
| JP (1) | JP7269227B2 (ja) |
| KR (1) | KR20200058496A (ja) |
| CN (1) | CN111278433A (ja) |
| AU (2) | AU2018341479B2 (ja) |
| BR (1) | BR112020006039A2 (ja) |
| CA (1) | CA3076907A1 (ja) |
| CL (1) | CL2020000747A1 (ja) |
| EA (1) | EA202090573A1 (ja) |
| IL (1) | IL273282A (ja) |
| MA (1) | MA50657A (ja) |
| MX (1) | MX2020003760A (ja) |
| PH (1) | PH12020550341A1 (ja) |
| SG (1) | SG11202002113TA (ja) |
| WO (1) | WO2019067634A1 (ja) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| EP3615513B1 (en) | 2017-04-24 | 2022-07-20 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| BR112019024135A2 (pt) | 2017-05-18 | 2020-06-02 | Tesaro, Inc. | Terapias de combinação para o tratamento de câncer |
| SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| IL297984A (en) * | 2020-05-08 | 2023-01-01 | Janssen Pharmaceutica Nv | Pharmaceutical formulations of abiraterone acetate and niraparib |
| BR112022024533A2 (pt) * | 2020-06-19 | 2022-12-27 | Glaxosmithkline Ip No 2 Ltd | Formulação compreendendo daprodustat |
| CA3199341A1 (en) * | 2020-11-20 | 2022-05-27 | Nikolaos DRAKOULIS | Ammonium chloride formulation to support human natural defense against viruses |
| WO2023159066A1 (en) | 2022-02-15 | 2023-08-24 | Tesaro, Inc. | Use of niraparib for the treatment of brain cancer |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9606337D0 (en) | 1996-03-26 | 1996-05-29 | Freeman Reginald E | Rheometer |
| AR030630A1 (es) | 2000-09-11 | 2003-08-27 | Novartis Ag | Composiciones farmaceuticas |
| AR052319A1 (es) | 2004-10-29 | 2007-03-14 | Kalypsys Inc | Compuestos biciclicos sustituidos por sulfonilo en funcion de moduladores del ppar |
| GB0700432D0 (en) | 2007-01-10 | 2007-02-21 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| GB0606663D0 (en) | 2006-04-03 | 2006-05-10 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| WO2007113596A1 (en) | 2006-04-03 | 2007-10-11 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Amide substituted indazole and benzotriazole derivatives as poly(adp-ribose)polymerase (parp) inhibitors |
| WO2008043024A2 (en) * | 2006-10-04 | 2008-04-10 | Kalypsys, Inc. | Oral pharmaceutical formulation comprising a sulfonyl bicyclic modulator of ppar for the treatment of disease |
| KR101591656B1 (ko) | 2007-01-10 | 2016-02-19 | 엠에스디 이탈리아 에스.알.엘. | 폴리(ａｄｐ-리보오스) 폴리머라아제(ｐａｒｐ) 억제제로서의 아미드 치환된 인다졸 |
| RS52633B (en) | 2007-01-16 | 2013-06-28 | Bipar Sciences Inc. | CANCER TREATMENT FORMULATION |
| BRPI0817537B1 (pt) | 2007-10-17 | 2022-04-05 | Kudos Pharmaceuticals Limited | 4-[3-(4-ciclopropanocarbonil-piperazina-1-carbonil)-4-fluoro-benzil]-2h-ftalazin-1-ona, método para obtê-lo, composição farmacêutica compreendendo o mesmo, bem como usos terapêuticos do dito composto |
| RU2495035C2 (ru) | 2008-01-08 | 2013-10-10 | Мерк Шарп Энд Домэ Лтд | Фармацевтически приемлемые соли 2-{4-[(3s)-пиперидин-3-ил]фенил}-2н-индазол-7-карбоксамида |
| US20100278921A1 (en) | 2009-04-30 | 2010-11-04 | Fischer Cristina M | Solid oral formulation of abt-263 |
| US20100297194A1 (en) | 2009-04-30 | 2010-11-25 | Nathaniel Catron | Formulation for oral administration of apoptosis promoter |
| CA2772328C (en) | 2009-08-26 | 2017-06-20 | Cephalon, Inc. | Novel forms of a multicyclic compound |
| CA2779052A1 (en) | 2012-05-31 | 2013-11-30 | Pharmascience Inc. | Pharmaceutical composition of entecavir and process of manufacturing |
| PT2928865T (pt) | 2012-12-07 | 2018-06-11 | Merck Sharp & Dohme | Processo de transaminação biocatalítica |
| EP2928473B1 (en) | 2012-12-07 | 2017-06-28 | Merck Sharp & Dohme Corp. | Regioselective n-2 arylation of indazoles |
| JP2016519684A (ja) * | 2013-04-08 | 2016-07-07 | デニス エム ブラウン | 準最適に投与された薬物療法の有効性を改善するための及び／又は副作用を低減するための方法および組成物 |
| RU2723050C2 (ru) | 2013-05-02 | 2020-06-08 | Анаптисбайо, Инк. | Антитела, направленные к белку запрограммированной гибели клетки-1 (pd-1) |
| US9191894B2 (en) | 2013-07-23 | 2015-11-17 | Disney Enterprises, Inc. | Power saving for multi-hop communications |
| EP3089965B1 (en) * | 2014-01-05 | 2018-08-29 | Washington University | Radiolabeled tracers for poly (adp-ribose) polymerase-1 (parp-1), methods and uses therefor |
| EP3134088B1 (en) | 2014-04-22 | 2019-04-10 | Calitor Sciences, LLC | Bicylcic pyrazolone compounds and methods of use |
| US9987275B2 (en) * | 2014-04-23 | 2018-06-05 | The Brigham And Women's Hospital, Inc. | Targeting PARP1 for treatment of TSC and cancers |
| EP3148336B1 (en) | 2014-05-28 | 2019-10-02 | Eisai R&D Management Co., Ltd. | Eribulin and poly (adp ribose) polymerase (parp) inhibitors as combination therapy for the treatment of cancer |
| CN106794185A (zh) * | 2014-08-22 | 2017-05-31 | 克洛维斯肿瘤有限公司 | Rucaparib的高剂量强度片剂 |
| WO2016094391A1 (en) | 2014-12-08 | 2016-06-16 | Myriad Genetics, Inc. | Methods and materials for predicting response to niraparib |
| MA41463A (fr) | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
| JP7149076B2 (ja) | 2015-03-03 | 2022-10-06 | ファーマサイクリックス エルエルシー | ブルトン型チロシンキナーゼ阻害剤の薬学的製剤 |
| MA41867A (fr) | 2015-04-01 | 2018-02-06 | Anaptysbio Inc | Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3) |
| KR102632745B1 (ko) | 2015-04-06 | 2024-02-01 | 얀센 파마슈티카 엔브이 | 이브루티닙을 함유하는 조성물 |
| CN108349978B (zh) | 2015-07-02 | 2021-07-23 | 安塞塔制药公司 | (S)-4-(8-氨基-3-(1-(丁-2-炔酰基)吡咯烷-2-基)咪唑并[1,5-a]吡嗪-1-基)-N-(吡啶-2-基)苯甲酰胺的固体形式和制剂 |
| AU2016303489B2 (en) | 2015-07-31 | 2023-02-16 | University Of Florida Research Foundation, Inc. | Hematopoietic stem cells in combinatorial therapy with immune checkpoint inhibitors against cancer |
| WO2017125423A1 (en) | 2016-01-19 | 2017-07-27 | Janssen Pharmaceutica Nv | Formulations/compositions comprising a btk inhibitor |
| WO2017210608A1 (en) | 2016-06-02 | 2017-12-07 | Yale University | Compositions and methods for targeting and treating homologous recombination-deficient tumors |
| KR20230042136A (ko) | 2016-06-29 | 2023-03-27 | 테사로, 인코포레이티드 | 난소암의 치료 방법 |
| CN106496187A (zh) | 2016-09-14 | 2017-03-15 | 陕西科技大学 | 一种制备PARP抑制剂Niraparib的合成方法 |
| AU2017354071A1 (en) | 2016-11-01 | 2019-05-23 | Anaptysbio, Inc. | Antibodies directed against T cell immunoglobulin and mucin protein 3 (TIM-3) |
| CN110049777A (zh) | 2016-11-01 | 2019-07-23 | 安奈普泰斯生物有限公司 | 针对程序性死亡-1(pd-1)的抗体 |
| CN106831708A (zh) | 2016-11-22 | 2017-06-13 | 西安泰科迈医药科技股份有限公司 | 一种新型口服抗癌药物Nirapairb的合成方法 |
| CN108201537A (zh) | 2016-12-16 | 2018-06-26 | 苏州苏融生物医药有限公司 | 一种尼拉帕尼缓控释药物组合物及其用途 |
| CN106854176A (zh) * | 2016-12-21 | 2017-06-16 | 南京艾德凯腾生物医药有限责任公司 | 一种制备尼拉帕尼对甲苯磺酸盐一水合物的方法 |
| WO2018122168A1 (en) * | 2016-12-29 | 2018-07-05 | Bayer Pharma Aktiengesellschaft | Combinations of bub1 kinase and parp inhibitors |
| TWI793094B (zh) | 2017-01-09 | 2023-02-21 | 美商提薩羅有限公司 | 用抗tim-3抗體治療癌症之方法 |
| MX2019008207A (es) | 2017-01-09 | 2019-12-11 | Tesaro Inc | Métodos para tratar el cáncer con anticuerpos anti-pd-1. |
| CN110944638A (zh) | 2017-03-27 | 2020-03-31 | 特沙诺有限公司 | 尼拉帕尼组合物 |
| EA201992162A1 (ru) | 2017-03-27 | 2020-02-28 | Тесаро, Инк. | Составы на основе нирапариба |
| EP3615513B1 (en) | 2017-04-24 | 2022-07-20 | Tesaro, Inc. | Methods of manufacturing of niraparib |
| MX2019012793A (es) | 2017-04-27 | 2020-02-13 | Tesaro Inc | Agentes anticuerpos dirigidos contra el gen de activación de linfocitos-3 (lag-3) y usos de los mismos. |
| CN110831580A (zh) | 2017-05-09 | 2020-02-21 | 特沙诺有限公司 | 用于治疗癌症的组合疗法 |
| BR112019024135A2 (pt) | 2017-05-18 | 2020-06-02 | Tesaro, Inc. | Terapias de combinação para o tratamento de câncer |
| CN108530425A (zh) | 2017-05-27 | 2018-09-14 | 广州科锐特生物科技有限公司 | 一种尼拉帕尼对甲苯磺酸盐水合物晶型及其制备方法 |
| SG11202002113TA (en) | 2017-09-26 | 2020-04-29 | Tesaro Inc | Niraparib formulations |
| WO2019067978A1 (en) | 2017-09-30 | 2019-04-04 | Tesaro, Inc. | POLYTHERAPIES FOR THE TREATMENT OF CANCER |
| SG11202002499TA (en) | 2017-10-06 | 2020-04-29 | Tesaro Inc | Combination therapies and uses thereof |
| CA3087060A1 (en) | 2017-12-27 | 2019-07-04 | Tesaro, Inc. | Methods of treating cancer |
| CN111918667A (zh) | 2018-02-05 | 2020-11-10 | 特沙诺有限公司 | 儿科尼拉帕尼配制剂和儿科治疗方法 |
-
2018
- 2018-09-26 SG SG11202002113TA patent/SG11202002113TA/en unknown
- 2018-09-26 CN CN201880062593.0A patent/CN111278433A/zh active Pending
- 2018-09-26 MX MX2020003760A patent/MX2020003760A/es unknown
- 2018-09-26 KR KR1020207011938A patent/KR20200058496A/ko not_active Application Discontinuation
- 2018-09-26 BR BR112020006039-9A patent/BR112020006039A2/pt unknown
- 2018-09-26 AU AU2018341479A patent/AU2018341479B2/en active Active
- 2018-09-26 EA EA202090573A patent/EA202090573A1/ru unknown
- 2018-09-26 MA MA050657A patent/MA50657A/fr unknown
- 2018-09-26 EP EP18786585.2A patent/EP3687505A1/en active Pending
- 2018-09-26 CA CA3076907A patent/CA3076907A1/en active Pending
- 2018-09-26 JP JP2020517352A patent/JP7269227B2/ja active Active
- 2018-09-26 US US16/650,948 patent/US11730725B2/en active Active
- 2018-09-26 WO PCT/US2018/052979 patent/WO2019067634A1/en unknown
-
2020
- 2020-03-12 IL IL273282A patent/IL273282A/en unknown
- 2020-03-23 CL CL2020000747A patent/CL2020000747A1/es unknown
- 2020-03-26 PH PH12020550341A patent/PH12020550341A1/en unknown
-
2022
- 2022-01-27 AU AU2022200520A patent/AU2022200520A1/en not_active Abandoned
-
2023
- 2023-06-23 US US18/340,467 patent/US20240082231A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2022200520A1 (en) | 2022-02-17 |
| EA202090573A1 (ru) | 2020-09-07 |
| US11730725B2 (en) | 2023-08-22 |
| MX2020003760A (es) | 2020-07-29 |
| AU2018341479A1 (en) | 2020-04-16 |
| CA3076907A1 (en) | 2019-04-04 |
| BR112020006039A2 (pt) | 2020-10-06 |
| WO2019067634A1 (en) | 2019-04-04 |
| JP2020535158A (ja) | 2020-12-03 |
| KR20200058496A (ko) | 2020-05-27 |
| CL2020000747A1 (es) | 2020-09-25 |
| IL273282A (en) | 2020-04-30 |
| AU2018341479B2 (en) | 2022-02-17 |
| US20240082231A1 (en) | 2024-03-14 |
| MA50657A (fr) | 2020-08-05 |
| TW201927304A (zh) | 2019-07-16 |
| JP7269227B2 (ja) | 2023-05-08 |
| CN111278433A (zh) | 2020-06-12 |
| US20200289494A1 (en) | 2020-09-17 |
| EP3687505A1 (en) | 2020-08-05 |
| PH12020550341A1 (en) | 2021-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL273541A (en) | formulations | |
| IL268697A (en) | Formulations | |
| IL269630A (en) | Niraprib formulations | |
| IL269621A (en) | Niraparib formulations | |
| IL273282A (en) | Niraprib formulations | |
| IL265609A (en) | New formulations | |
| GB201607918D0 (en) | Novel formulations | |
| IL274139A (en) | Sprayable formulation | |
| GB201707189D0 (en) | Novel formulations | |
| GB201701239D0 (en) | Novel formulation | |
| GB201707188D0 (en) | Novel formulations | |
| IL274719A (en) | formulation | |
| GB201713724D0 (en) | Formulation | |
| GB201706969D0 (en) | Formulation | |
| GB201707187D0 (en) | Novel formulations | |
| IL254075A (en) | Pesticide Resistant Remedies | |
| IL268195A (en) | Solid fosmetpantothenate formulations | |
| GB201714461D0 (en) | Formulations | |
| SG11202011823SA (en) | Activator-nucleator formulations | |
| GB201716291D0 (en) | Novel formulations | |
| GB201819028D0 (en) | Butanol-based formulations | |
| GB2568045B (en) | Formulation | |
| GB201707562D0 (en) | Novel formulations | |
| GB201707564D0 (en) | Novel formulations | |
| GB201707190D0 (en) | Novel Formulations |